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Abstract
To evaluate differences in use of sentinel lymph node biopsy (SLNB) by age and race in Medicare
recipients with early-stage breast cancer, we examined Surveillance, Epidemiology and End
Results—Medicare linked data for women undergoing breast conserving surgery for stage I or II
breast cancer, including axillary staging, between January 2000 and December 2002.
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Multivariable generalized linear modeling with generalized estimating equations was used to
identify predictors of receiving SLNB versus standard axillary lymph node dissection as the
primary axillary staging modality. Women were significantly less likely to receive SLNB as their
primary staging procedure if they were African American (OR 0.65), greater than 80 years of age
(OR 0.71 vs. age <70), or dually eligible for Medicare and Medicaid (OR 0.61). Tumor
characteristics, including well-differentiated histology and stage I disease, were associated with
increased likelihood of SLNB, but estrogen receptor status was not a significant predictor. Women
treated at an institution affiliated with an NCI cooperative research group had significantly greater
likelihood of receiving SLNB (OR 2.31). Likelihood of receiving SLNB increased for women
diagnosed in 2001 and 2002 compared with 2000. Significant disparities exist in receipt of SLNB
in the Medicare population, with African Americans, the elderly, and economically disadvantaged
patients being less likely to receive this innovative and morbidity-sparing procedure. These
findings continue a previously observed pattern of reduced access to state of the art breast cancer
care among underserved populations.
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Background and rationale
Axillary lymph node staging and treatment play a vital role in the prognosis and control of
breast cancer. Metastasis to the regional lymph nodes is the most important prognostic factor
for recurrence and mortality, and for some patients the removal of axillary nodes can
improve local disease control and survival [1,2]. However, these benefits come at the price
of considerable surgical morbidity, which has led to the development of innovative surgical
techniques to replace traditional axillary lymph node dissection (ALND). Sentinel lymph
node biopsy (SLNB) is an alternative staging method that enables the surgeon to sample and
more thoroughly examine the lymph nodes most likely to contain metastases.
Sentinel lymph node biopsy has been widely adopted for clinical use in the United States
beginning in the late 1990s. Although false negative results are possible [3], associated
morbidities including lymphedema, wound infections, axillary seromas, and paresthesias are
significantly less frequent than in ALND [4]. A recently reported clinical trial found no
significant differences in regional control or survival between the two procedures [5,6].
Following the pattern of other treatments for early-stage breast cancer, SLNB has been
underused in vulnerable populations [7,8]. Older age, ethnic minority status, and lower
socioeconomic status have been associated with lower SLNB rates. Lack of health
insurance, coverage by Medicare or Medicaid, and treatment at a non-academic facility have
been associated with lower odds of receiving SLNB in early-stage breast cancer patients [8].
However, the effect of institutional characteristics on SLNB rates has yet to be well
characterized, particularly in minorities.
Racial disparities exist in multiple other aspects of breast cancer treatment. African
Americans experience lower rates of axillary lymph node staging [9], definitive local
treatment [10,11], adjuvant radiation [10-14], chemotherapy and endocrine treatment [10],
as well as post-treatment mammography surveillance [13,15]. Treatments are more likely to
be delayed, and African-American woman are more frequently treated at hospitals with poor
adherence to breast cancer treatment guidelines [15]. These disparities, along with lower
screening rates, are widely believed to contribute to the racial gap in overall and stage-
specific survival [16,17].
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Similar patterns of disparities exist among elderly breast cancer patients. Older women are
less likely to receive axillary lymph node staging [18,19], adjuvant radiation, and
surveillance mammography, even after adjustment for co-morbidities [13]. Physician
recommendations for adjuvant treatment [20], as well as chemotherapy rates, decrease with
age [19,21], despite evidence that healthy older women derive significant benefit from
standard adjuvant chemotherapy with reasonable toxicity [22-24]. Breast cancer-specific
survival declines with advancing age, and this difference appears to be mediated by under
treatment [21]. However, the racial gap in stage-specific survival appears to be attenuated in
patients over age 65 [16], which may reflect improved access to care through Medicare
coverage.
This study uses the Surveillance Epidemiology and End Results (SEER)-Medicare database
to examine racial and age-related disparities in the use of SLNB. To our knowledge, this
study is the first to examine disparities in SLNB among Medicare patients, who compose
approximately 40% of new US breast cancer cases annually [25]. Further, this study controls
at a more detailed level than previous analyses for institutional characteristics that have been
previously suggested to influence cancer treatment disparities, including surgical volume,
NCI affiliation, and involvement in cancer research networks [15,26-28]. In addition, the use
of a Medicare patient sample enables examination of the hypothesis that increased access to
health insurance may narrow breast cancer treatment disparities in this population.
Methods
Data
Data were obtained from the SEER-Medicare linked data, which have been previously
described [29]. SEER-Medicare reflects the linkage of the SEER cancer registries program
to administrative and claims data from Medicare. The SEER dataset represents roughly 25%
of the US cancer population, and the Medicare data provides health insurance coverage
information for 97% of Americans aged 65 and older. Together, these data include
demographic characteristics, incident cancer information, and specific data on inpatient and
outpatient cancer treatment and other health conditions. SEER-Medicare data offer a unique
opportunity to study differences in cancer treatment and outcomes among a large
population-based sample [29].
Study population
Data were extracted from SEER-Medicare linked data from January 2000 through December
2002. This time period was selected to permit examination of SLNB following its adoption
by Medicare and prior to changes in AJCC cancer staging as recorded by SEER beginning in
2003. The sample was restricted to Caucasian or African-American women, diagnosed with
stage I or II breast cancer as first or only primary cancer, aged 66 or older at date of
diagnosis, and receiving breast conserving surgery (BCS) including axillary staging.
Because we wished to examine racial disparities, only those SEER registries with 5% or
greater African Americans were examined, including San Francisco, Detroit, Atlanta, Los
Angeles, Rural Georgia, Louisiana, Kentucky and New Jersey. The sample included only
women with complete claims from 12 months before diagnosis until 24 months after
diagnosis. Claims were limited to procedures performed 1 month pre-diagnosis through 24
months post-diagnosis.
Independent and dependent variables
The primary outcome was receipt of SLNB. Patients were categorized as receiving SLNB if
their scope of regional lymph node surgery in SEER indicated sentinel node removal with or
without subsequent ALND, or if they had a Medicare CPT code for dye injection or
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lymphoscintigraphy. Patients were categorized as receiving primary ALND if none of the
above criteria for SLNB were met and if their scope of lymph node surgery in SEER-
specified removal of regional lymph nodes with at least 10 nodes examined, or if analogous
Medicare CPT codes were used. Patients who received SLNB followed by ALND were
categorized as having received SLNB. In the case of discordance between SEER and
Medicare, the patient was categorized as having SLNB if either database indicated that
SLNB had been performed. Race was ascertained from SEER data. Due to extremely small
sample sizes in other racial groups, the analysis was restricted to Caucasian and African-
American women.
Covariates
Patient information included race, age at diagnosis and marital status. Clinical and tumor
information included stage, grade, estrogen receptor status, and comorbidity index. Stage
was determined according to the American Joint Committee on Cancer TNM staging
system. Education level was assigned to each patient based on the 2000 census data for their
area of residence, measured in quartiles within each registry and then combined across
registries following previous methodology [15]. Medicare/Medicaid dual eligibility was
included in the model as a patient-level indicator of SES. Due to high correlation between
census level income and dual eligibility (Spearman correlation P = 0.01), only Medicaid
eligibility was included in the final model. Building from previous work [30], an indicator
variable was created to measure organizational affiliation with NCI Cooperative Groups
having breast cancer research portfolios, including the American College of Surgeons
Oncology Group, Eastern Cooperative Oncology Group, Cancer and Leukemia Group B,
Southwest Oncology Group, and the National Surgical Adjuvant Breast and Bowel Project
(ACOSOG, ECOG, CALGB, SWOG, NSABP, respectively).
Statistical analysis
To calculate the odds of receiving SLNB, a generalized linear model was fit using
generalized estimation equations (GEE) as implemented in the GENMOD procedure (logit
link function) in SAS 9.2 (SAS®, 2009). This procedure takes into account the clustering of
observations within hospitals when calculating estimates of association between covariates.
Receipt of SLNB was the dependent variable. Other variables in the final model are listed in
Table 2. To specifically examine effect modification by race, models were stratified, and
interaction terms between time and selected covariates were tested (data not presented). To
illustrate time trends across the study period, predicted probabilities from these models were
used to construct figures estimating the probability of SLNB over time by age and race
(Figs. 1, 2). We included a quadratic time estimate to relax the restriction of linear effects by
time and to facilitate better plotting of the estimates.
Results
Descriptive characteristics of the study sample are presented in Table 1. Although we
specifically selected SEER regions with significant African-American populations, the
percentage of such patients remained relatively low at 7.7%. The overall rate of SLNB was
68%. Case volume was distributed evenly over the 3-year study period. The overall sample
was distributed evenly over the range of census tract income and education levels. 8.7% of
patients were dually eligible for Medicare and Medicaid coverage. 80% were treated at an
institution affiliated with at least one NCI cooperative group participating in breast cancer
research.
In unadjusted analysis across all years, African Americans were roughly half as likely as
Caucasians to receive SLNB (OR 0.54, 95% CI 0.42–0.69, data not presented). Results of
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multivariable logistic regression modeling of potential predictors of SLNB are presented in
Table 2. African-American patients remained significantly less likely to receive SLNB than
white patients in adjusted analysis (OR = 0.65, 95% CI 0.50–0.85). There was an age-related
decline in receipt of SLNB, with women age 80 and above having 0.71 times the odds of
receiving the procedure compared to patients 65–69 (95% CI 0.57–0.87). Educational
attainment was not significantly associated with likelihood of receiving SLNB; however,
women enrolled in Medicaid had significantly lower odds of receiving the procedure (OR =
0.61, 95% CI 0.47–0.78). Medical co-morbidities as measured by Charlson index were not
significantly associated with the likelihood of receiving SLNB.
In order to more fully understand the relationship among race, age, and the receipt of SLNB
over time, additional modeling was performed with race-by-time and age-by-time
interaction terms. Results of this analysis are presented in Figs. 1 and 2. Rates of SLNB
among African Americans remained significantly lower than those for Caucasians
throughout the study period; however, there was variability in the adjusted rate of SLNB
among African-American woman over time, likely due to small sample size.
Tumor characteristics were significantly associated with use of SLNB, and overall, women
with lower risk tumor characteristics were more likely to receive SLNB. Specifically,
women with well-differentiated tumors were significantly more likely to receive the
procedure than those with poorly differentiated tumors. Likewise, women with stage I or
stage IIA tumors were more likely to undergo SLNB than those with IIB tumors. ER
positivity did not meet significance.
Use of SLNB also varied significantly by institution and over time. Treatment at a
cooperative group affiliated institution was associated with higher odds of receiving SLNB
(OR 2.31, 95% CI 1.50–5.61). Other institutional factors previously reported to influence
breast cancer care quality, including breast cancer-specific surgical volume and NCI center
designation, were also examined in exploratory analysis to evaluate whether adjustment for
these factors accounted for the observed racial disparities. These factors were not found to
be significant confounders. To examine the possibility that the effect of institutional
characteristics varied between African-Americans and Caucasians, interaction between race
and cooperative group affiliation was assessed. No significant effect modification was found
(data not presented).
Adoption of SLNB increased over time, with patients being significantly more likely to
receive SLNB in 2001 and 2002 compared to 2000. Organizational predictors of use of
SLNB were more closely examined in a separately published analysis using appropriate
methods for organization-level analysis [30].
There was significant geographic variability in receipt of SLNB. The New Jersey SEER
region had the highest rate of SLNB. Patients in the San Francisco, Detroit, Kentucky and
Louisiana regions were significantly less likely to receive SLNB. Treatment in the Georgia
or Los Angeles regions was not associated with a significant decrease in odds of receiving
SLNB.
Discussion
This study found significant disparities in the receipt of SLNB, an innovative and morbidity-
sparing procedure for early-stage breast cancer, among vulnerable populations including
African-American women, those of low socioeconomic status, and the elderly. These
disparities appear to persist over time, with only slight attenuation after controlling for
geographic and institutional factors. Our work confirms that disparities in SLNB follow the
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troubling pattern of reduced access to state of the art breast cancer care among underserved
populations.
Prior work has suggested that racial disparities in stage-specific breast cancer survival may
be narrowed in women over age 65 [16], presumably in part because Medicare eligibility
reduces disparities in access to care. However, we found that even among a population
composed entirely of Medicare recipients, African-American women were significantly less
likely to receive SLNB than Caucasian women. Our analysis controlled for other known
factors that might necessitate the more invasive ALND procedure in African-American
women, such as more advanced stage at diagnosis [31] and higher rates of mastectomy
[32,33], by limiting the sample to women undergoing breast conserving surgery and
adjusting for tumor stage. After adjustment for these factors, African-American women
remain significantly less likely to receive SLNB.
The omission of axillary staging in elderly women with breast cancer has been previously
documented [11,13,18,21,34]. Our study shows further that even among those who receive
axillary staging, very elderly women are less likely to receive SLNB. This finding is
particularly troubling considering that the principal benefit of SLNB lies in its reduced
morbidity, and the elderly are arguably the most in need of morbidity-sparing treatment.
This study found significantly lower rates of SLNB among Medicaid recipients, possibly
indicating reduced access to this procedure. The patient population dually eligible for
Medicare and Medicaid has been previously described to represent an extreme of low
socioeconomic status, and to have disproportionate rates of disability and medical co-
morbidity [35]. These patients may have a reduced choice of providers, may be poorly
equipped to advocate for themselves, and may have reduced access to information regarding
treatment options which could steer them toward institutions or physicians offering more
innovative care. Future analyses should consider using this indicator to examine
socioeconomic disparities in breast cancer care, and should continue to explore other
innovative ways of defining socioeconomic status in SEER-Medicare data.
Institutional affiliation with cooperative research groups was significantly associated with a
woman's likelihood of receiving SLNB. However, significant racial and age disparity
remained after controlling for cooperative group affiliation, and exploratory analysis failed
to show an effect of other institutional measures previously associated with quality and
outcomes, including breast cancer surgical volume and NCI center designation. These
findings suggest that choice of institution does not explain most or all of the racial and age
disparities in receipt of SLNB.
During the period of early adoption covered by our study, the technical accuracy of SLNB
as an axillary staging technique was well established through multiple single institution and
multi-center studies [36], and guidance on learning and performing the technique was
available in the surgical literature [37,38]. However, randomized data on the long term
outcomes of SLNB were not yet mature during the study period, and two randomized trials
of the technique by NCI cooperative groups were enrolling patients between 2000 and 2002.
It is likely that this ongoing research influenced our results, either directly by enrollment of
patients in the sample on SLNB clinical trials at participating institutions, or indirectly by
earlier dissemination of SLNB expertise to surgeons at participating institutions. The
decision by inexperienced surgeons and institutions to refrain from performing SLNB, as
recommended by guidelines at the time [37,38], may in fact reflect responsible patient care.
The hypothesized gap in surgical experience between research and non-research institutions
during the study period could disproportionately affect SLNB utilization among African
Americans to the extent that physicians serving minority and underserved populations were
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disproportionately affiliated with non-research institutions. Because the data in this analysis
are de-identified, it is not possible to ascertain precisely which patients were treated at
centers participating in ongoing SLNB trials. However, since the majority of clinical trial
enrollment is through academic centers, which are commonly located in urban centers and
disproportionately serve minority populations, it is a near certainty that minority populations
were served in institutions sponsoring the trials. In the two randomized multicenter trials
open during the study period, enrollment took place at 80 centers and 126 centers,
respectively, including academic medical centers, teaching hospitals, and community
centers, and 10% of participants were minorities [39,40]. It is clear that the number of
minority patients at these participating institutions was considerable, particularly given the
typically lower trial participation rates of minority populations compared to Caucasians.
The exclusion of women with no axillary staging, an omission which is known to occur
more frequently in the oldest patients [34], may have selected a high-risk, healthy cohort of
elderly women who can tolerate more extensive axillary surgery. However, multivariable
analysis controlled for both tumor stage/grade and co-morbidity, which should attenuate any
such selection bias. An initial sample was examined including stage I and II BCS patients
reported as “no regional lymph nodes removed” as well as those for whom regional lymph
node data was missing or unknown. This group comprised 15.9% of the initial sample (n =
732/4606), within the range of previously reported estimates of omission of axillary staging
in breast conserving therapy patients in this age group [18]. To assess the risk of bias,
preliminary modeling combined these women with the ALND group and found no
significant changes in outcomes.
The inclusion of AJCC stage II patients presents a challenge for interpretation, due to the
presence of node-negative and node-positive patients in the same subgroup. Because it is not
possible to distinguish staging based on clinical versus pathologic information in this
dataset, it is possible that some women had clinically detectable lymph node disease
preoperatively and would be unlikely to be considered for SLNB. We therefore controlled
for tumor stage using the most specific available subgroups and obtained a logical result
showing decreased use of SLNB among women at higher risk of metastasis. Given that the
majority of women with stage II breast cancers do not have clinically evident nodal disease
prior to surgery, it is likely that other factors play a role in receipt of SLNB in this group.
Our findings for the most part mirror reports of race and age disparities in prior analysis of
SLNB in other populations. Two prior studies of early-stage breast cancer patients in the
National Cancer Database found a lower likelihood of SLNB among patients age 72 or
older, African Americans, and those with Medicaid or no insurance, although dual eligibility
was not specifically examined [7,8]. Examination of SLNB rates in melanoma found lower
rates among patients older than 75 years, minority patients, and those with Medicaid [27].
The work presented here is the first to examine the Medicare population specifically and to
establish that disparities in access to SLNB by race, age, and socioeconomic status do not
appear to be significantly attenuated by access to Medicare coverage.
Despite the selection of SEER registries with relatively higher minority participation during
the study period, the proportion of African-American patients in our sample remained
relatively low. We chose to focus this manuscript on the critical period from 2000 to 2002 in
order to capture patterns of use immediately after Medicare began reimbursing for the SLNB
procedure but before changes in AJCC staging as recorded by the SEER registries in 2003,
the inclusion of which would confound consistent inclusion criteria and sample selection. In
the future, we plan to apply similar analytic techniques to data from 2003 forward. We
anticipate that examination of newer data will provide a larger minority sample, and reflect
maturing patterns of adoption of the SLNB technique.
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This study demonstrates significant and troubling disparities in the receipt of SLNB among
breast cancer patients. African-American women have significantly lower rates of SLNB,
which are not fully explained by adjustment for disease characteristics, socioeconomic and
institutional factors. Patients who stand to benefit substantially from reduced surgical
morbidity, including the elderly and those with fewer economic resources, are paradoxically
less likely to receive a procedure that offers them this benefit. In light of recent findings
confirming that SLNB offers disease control and survival outcomes equivalent to those of
axillary dissection, it is important to ensure appropriate use of this innovation which offers
improved quality of life to breast cancer survivors. Given that Medicare coverage does not
appear to resolve race and age-based disparities in receipt of this state of the art treatment,
and that such disparities exist across a variety of institutions, providers should examine the
decision-making process regarding SLNB in their own practice environments, and consider
how best to deliver SLNB to the widest possible range of eligible patients.
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Estimated SLNB rates by race 2000–2002. *Adjusted for age, marital status, medicaid
eligibility, comorbidity score, educational attainment, tumor grade and stage, ER status,
institutional coop group affiliation, SEER region
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Estimated SLNB rates by age 2000–2002. *Adjusted for age, marital status, medicaid
eligibility, comorbidity score, educational attainment, tumor grade and stage, ER status,
institutional coop group affiliation, SEER region
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Table 1
Characteristics of study patients
Patient characteristics Frequency %
Race
 Caucasian 3574 92.3
 African American 300 7.7
Age
 65–69 941 24.3
 70–74 1183 30.5
 75–79 1071 27.7
 80 plus 679 17.5
Marital status
 Unmarried 2102 54.3
 Married 1772 45.7
Dual eligibility for medicare/medicaid
 No 3536 91.3
 Yes 338 8.7
Comorbidity Score
 0 2578 66.6
 1 1040 26.9
 2 256 6.6
Educational attainment (census tract level)
 Above 75th percentile HS graduates 984 25.4
 50–75th percentile 978 25.3
 25–50th percentile 955 24.7
 Below 25th percentile 952 24.6
Tumor Stage
 Stage I 2545 65.7
 Stage IIA 986 25.5
 Stage IIB or NOS 343 8.9
Tumor grade
 Well differentiated 961 24.8
 Moderately differentiated 1586 40.9
 Poorly differentiated 943 24.3
 Unknown, not assessed 384 9.9
Estrogen receptor status
 Positive 2825 72.9
 Negative 437 11.3
 Unknown 612 15.8
Year of diagnosis
 2000 1279 33.0
 2001 1281 33.1













Reeder-Hayes et al. Page 15
Patient characteristics Frequency %
 2002 1314 33.9
Region
 San Francisco 224 5.8
 Detroit 683 17.6
 Atlanta/rural Georgia 271 7.0
 Los Angeles 591 15.3
 Kentucky 470 12.1
 Louisiana 328 8.5
 New Jersey 1307 33.7
Treating institution affiliated with NCI cooperative group*
 No 774 20.0
 Yes 3100 80.0
*
CALGB, ECOG, SWOG, NSABP, ACOSOG
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Table 2
Results of multivariate logistic regression
OR Lower 95% CI Upper 95% CI
Race
 African American 0.65 0.50 0.85
 Caucasian 1.00 N/a N/a
Age (reference = 65–69)
 70–74 0.90 0.76 1.08
 75–79 0.84 0.70 1.01
 80 plus 0.71 0.57 0.87
Marital status (ref. = married)
 Unmarried 0.93 0.83 1.06
Dual medicare/medicaid eligible (ref. = no)
 Yes 0.61 0.47 0.78
Comorbidity Score (ref. = 2 or more)
 0 0.88 0.68 1.15
 1 0.78 0.60 1.02
Census tract education (ref. = below 25th percentile)
 75th percentile HS graduates 1.14 0.94 1.37
 50–74th percentile 1.17 0.98 1.40
 25–49th percentile 1.09 0.91 1.31
Tumor AJCC stage (ref. = stage IIB)
 Stage I 1.90 1.50 2.40
 Stage IIA 1.61 1.28 2.04
Tumor grade (ref. =poorly differentiated)
 Unknown/not assessed 1.16 0.92 1.47
 Moderately differentiated 1.14 0.97 1.34
 Well differentiated 1.29 1.05 1.58
Estrogen receptor status (ref. = positive)
 Negative 0.84 0.69 1.03
 Unknown 0.98 0.80 1.19
Year of diagnosis (ref. = 2000)
 2001 1.59 1.32 1.92
 2002 2.21 1.72 3.10
Region (ref. = New Jersey)
 San Francisco 0.44 0.22 0.89
 Detroit 0.40 0.27 0.61
 Atlanta/rural Georgia 0.70 0.39 1.26
 Los Angeles 0.85 0.57 1.26
 Kentucky 0.50 0.32 0.76
 Louisiana 0.42 0.26 0.66
Treating institution affiliated with cooperative group*
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OR Lower 95% CI Upper 95% CI
 Yes 2.31 1.50 5.61
*
CALGB, ECOG, SWOG, NSABP, ACOSOG
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